The outcome of studies using Toujeo (insulin glargine 300 units/mL) in patients with Type 1 and Type 2 Diabetes: expanding the evidence base

Symposium sponsored by Sanofi Presented at the ABCD Autumn Meeting 2018
Chairman introduction, Professor Mike Baxter, Sanofi
BRIGHT study: Results of the first head-to-head randomised clinical trial comparing the efficacy and safety of Toujeo vs insulin degludec in T2 Diabetes. Prof Vinod Patel Nuneaton